243 related articles for article (PubMed ID: 29169331)
21. Secondary prevention of atherothrombotic cerebrovascular events.
Paciaroni M
Curr Vasc Pharmacol; 2014 May; 12(3):365-72. PubMed ID: 24846225
[TBL] [Abstract][Full Text] [Related]
22. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA.
Ovbiagele B; Hills NK; Saver JL; Johnston SC
Neurology; 2006 Feb; 66(3):313-8. PubMed ID: 16476928
[TBL] [Abstract][Full Text] [Related]
23. Secondary prevention of stroke in Italy: a cross-sectional survey in family practice.
Filippi A; Bignamini AA; Sessa E; Samani F; Mazzaglia G
Stroke; 2003 Apr; 34(4):1010-4. PubMed ID: 12637698
[TBL] [Abstract][Full Text] [Related]
24. Secondary stroke prevention: review of clinical trials.
Elkind MS
Clin Cardiol; 2004 May; 27(5 Suppl 2):II25-35. PubMed ID: 15188933
[TBL] [Abstract][Full Text] [Related]
25. Secondary prevention after ischemic stroke or transient ischemic attack.
Bangalore S; Schwamm L; Smith EE; Singh IM; Liang L; Fonarow GC; Bhatt DL;
Am J Med; 2014 Aug; 127(8):728-38. PubMed ID: 24681258
[TBL] [Abstract][Full Text] [Related]
26. Associations between Ischemic Stroke Follow-Up, Socioeconomic Status, and Adherence to Secondary Preventive Drugs in Southern Sweden: Observations from the Swedish Stroke Register (Riksstroke).
Ullberg T; Glader EL; Zia E; Petersson J; Eriksson M; Norrving B
Neuroepidemiology; 2017; 48(1-2):32-38. PubMed ID: 28237982
[TBL] [Abstract][Full Text] [Related]
27. Secondary prevention of ischemic stroke in urban China.
Wei JW; Wang JG; Huang Y; Liu M; Wu Y; Wong LK; Cheng Y; Xu E; Yang Q; Arima H; Heeley EL; Anderson CS;
Stroke; 2010 May; 41(5):967-74. PubMed ID: 20224061
[TBL] [Abstract][Full Text] [Related]
28. Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke.
Shrestha S; Coy S; Bekelis K
Curr Pharm Des; 2017; 23(9):1377-1391. PubMed ID: 28003013
[TBL] [Abstract][Full Text] [Related]
29. Impact of the additive effect of angiotensin-converting enzyme inhibitors and /or statins with antiplatelet medication on mortality after acute ischaemic stroke.
Hassan Y; Al-Jabi SW; Aziz NA; Looi I; Zyoud SH
Basic Clin Pharmacol Toxicol; 2012 Apr; 110(4):370-7. PubMed ID: 22023326
[TBL] [Abstract][Full Text] [Related]
30. Secondary prevention of stroke: a practical guide to drug treatment.
Koennecke HC
CNS Drugs; 2004; 18(4):221-41. PubMed ID: 15015903
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulants versus antiplatelet agents for acute ischemic stroke.
Hankey GJ; Berge E; Sandercock P
Stroke; 2003 Jun; 34(6):1571-2. PubMed ID: 12764231
[No Abstract] [Full Text] [Related]
32. Risk factors and treatment at recurrent stroke onset: results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study.
Leoo T; Lindgren A; Petersson J; von Arbin M
Cerebrovasc Dis; 2008; 25(3):254-60. PubMed ID: 18216468
[TBL] [Abstract][Full Text] [Related]
33. Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke.
Hackam DG; Kapral MK
Can J Neurol Sci; 2004 Aug; 31(3):295-303. PubMed ID: 15376471
[TBL] [Abstract][Full Text] [Related]
34. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
[TBL] [Abstract][Full Text] [Related]
35. Recording a diagnosis of stroke, transient ischaemic attack or myocardial infarction in primary healthcare and the association with dispensation of secondary preventive medication: a registry-based prospective cohort study.
Dahlgren C; Geary L; Hasselström J; Rehnberg C; Schenck-Gustafsson K; Wändell P; Euler MV
BMJ Open; 2017 Sep; 7(9):e015723. PubMed ID: 28939569
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology and secondary prevention of ischemic stroke in patients on antiplatelet drug: a retrospective cohort study.
Gallo A; Galliazzo S; Grazioli S; Guasti L; Ageno W; Squizzato A
J Thromb Thrombolysis; 2019 Aug; 48(2):336-344. PubMed ID: 31177486
[TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy prior to and in acute haemorrhagic stroke. The use of pharmacotherapy and drugs associated outcomes in real-world practice - findings from the Polish Hospital Stroke Registry.
Niewada M; Skowrońska M; Sarzyńska-Długosz IM; Kamiński B; Kobayashi A; Członkowska A
Neurol Neurochir Pol; 2013; 47(6):517-24. PubMed ID: 24374996
[TBL] [Abstract][Full Text] [Related]
38. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
Høgh AL
Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
[TBL] [Abstract][Full Text] [Related]
39. Antihypertensive medications prescribed at discharge after an acute ischemic cerebrovascular event.
Ovbiagele B; Hills NK; Saver JL; Johnston SC
Stroke; 2005 Sep; 36(9):1944-7. PubMed ID: 16051895
[TBL] [Abstract][Full Text] [Related]
40. Use of antihypertensive medication after ischemic stroke in young adults and its association with long-term outcome.
van Dongen MME; Aarnio K; Martinez-Majander N; Pirinen J; Sinisalo J; Lehto M; Kaste M; Tatlisumak T; de Leeuw FE; Putaala J
Ann Med; 2019 Feb; 51(1):68-77. PubMed ID: 30592437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
